PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

Phase 3

Completed

Conditions: Maxillary Sinusitis

Interventions: Other: placebo
Drug: levofloxacin

First Posted Date: 2008-03-26

Last Posted Date: 2011-05-11

Lead Sponsor: Pfizer

Target Recruit Count: 541

Registration Number: NCT00643409

Locations: Pfizer Investigational Site

Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: SBI-087

First Posted Date: 2008-03-24

Last Posted Date: 2023-09-13

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT00641225

Locations: 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada

Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Celecoxib

First Posted Date: 2008-03-20

Last Posted Date: 2009-03-16

Lead Sponsor: Pfizer

Target Recruit Count: 270

Registration Number: NCT00639483

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

Phase 4

Completed

Conditions: Pain

Interventions: Drug: morphine sulfate extended release capsules

First Posted Date: 2008-03-20

Last Posted Date: 2012-06-11

Lead Sponsor: Pfizer

Target Recruit Count: 1570

Registration Number: NCT00640042

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: Placebo
Biological: PF-04603629

First Posted Date: 2008-03-19

Last Posted Date: 2009-07-31

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT00638313

Locations: 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States

A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury

Phase 4

Terminated

Conditions: Brain Injuries
Growth Hormone Deficiency Dwarfism

Interventions: Genetic: somatropin

First Posted Date: 2008-03-18

Last Posted Date: 2008-04-01

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT00638053

Locations: 🇺🇸
Pfizer Investigational Site, Federal Way, Washington, United States

Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

Phase 4

Terminated

Conditions: Arthritis, Juvenile Rheumatoid

Interventions: Drug: Sulfasalazine

First Posted Date: 2008-03-18

Last Posted Date: 2017-02-23

Lead Sponsor: Pfizer

Target Recruit Count: 2

Registration Number: NCT00637780

Locations: 🇲🇽
Private Office, Guadalajara, Jalisco, Mexico
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Advanced MDS

Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous

First Posted Date: 2008-03-17

Last Posted Date: 2021-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00637052

Locations: 🇺🇸
Emory University School of Medicine, Winship Cancer Center, Atlanta, Georgia, United States
🇺🇸
University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

Phase 1

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: PF-04603629
Biological: Placebo

First Posted Date: 2008-03-17

Last Posted Date: 2009-07-31

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT00637338

Locations: 🇺🇸
Pfizer Investigational Site, Portland, Oregon, United States

A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Parecoxib Sodium/Valdecoxib
Drug: Placebo/Valdecoxib
Other: Placebo/Placebo

First Posted Date: 2008-03-14

Last Posted Date: 2008-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 1671

Registration Number: NCT00636064

Locations: 🇬🇧
Pfizer Investigational Site, Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy